Chronic renal failure and albuminuria increase cardiovascular risk in patients with DM2 in proportion to the degree to which they occur and from their earliest stages [1]. At present, only two drugs are known to decrease cardiovascular mortality and provide nephroprotection, namely empagliflozin (analysed in the EMPAREG-OUTCOME study [2]) and liraglutide (according to the LEADER study [3]).
